bclxl
bclw
compon
cellsignal
network
govern
cell
surviv
cell
death
respons
differ
stimuli
virus
hypothesis
chemic
inhibitor
bclxl
bclw
could
modul
surviv
death
virusinfect
cell
studi
effect
anticanc
agent
surviv
noncancer
human
macrophag
respons
iav
cell
treat
infect
iav
mock
cell
surviv
monitor
indic
time
noncytotox
concentr
acceler
death
iavinfect
cell
figur
cell
death
depend
dose
multipl
viral
infect
figur
c
interestingli
treatment
slightli
attenu
product
infecti
viru
particl
figur
thu
noncytotox
concentr
anticanc
sensitis
noncancer
cell
iavinduc
death
next
studi
effect
analogu
death
iavinfect
cell
found
structur
analogu
acceler
death
iavinfect
human
macrophag
contrast
two
bclxl
bclwinhibitor
gossypol
ineffect
sensitis
cell
iavinduc
death
figur
supplementari
figur
effect
restrict
specif
macrophag
prepar
cell
line
iav
strain
figur
c
furthermor
acceler
death
variou
cell
type
infect
influenza
b
orthomyxovirida
bunyamwera
bunyavirida
semliki
forest
sindbi
togavirida
herp
simplex
herpesvirida
vaccinia
poxivirida
measl
paramyxovirida
echoviru
picornavirida
kaposi
sarcomaassoci
herp
herpesvirida
tickborn
enceph
dengu
virus
flavivirida
figur
supplementari
figur
result
suggest
structur
analogu
sensitis
cell
virusmedi
kill
confirm
bclxl
bclw
essenti
cell
surviv
upon
viral
infect
address
mechan
action
virusinfect
cell
first
analys
stage
iav
infect
trigger
cell
death
use
three
known
inhibitor
iav
infect
obatoclax
saliphenylhalamid
gemcitabin
target
myeloid
cell
vacuolar
atpas
vatpas
ribonucleotid
reductas
rnr
vatpas
necessari
endocyt
uptak
iav
cytoplasm
wherea
rnr
essenti
viral
rna
transcript
replic
nuclei
infect
cell
found
obatoclax
saliphenylhalamid
gemcitabin
rescu
iavinfect
retin
pigment
epithelium
rpe
cell
death
figur
second
perform
timeofcompoundaddit
experi
demonstr
kill
iavinfect
rpe
cell
independ
time
addit
figur
result
indic
sensitis
cell
death
multipl
stage
iav
infect
follow
viru
endocyt
uptak
shown
target
bclxl
bclw
mitochondria
disrupt
interact
bad
bax
bak
protein
initi
cancer
cell
test
whether
affect
interact
noncancer
iavinfect
human
cell
immunofluoresc
experi
show
immunoprecipit
ip
experi
confirm
noncytotox
concentr
displac
bad
bclxl
mitochondria
iav
facilit
process
figur
figur
thu
destabilis
interact
bclxl
bclw
bad
bax
bak
mitochondria
noncancer
cell
infect
iav
cell
bclxl
bclw
interact
limit
bad
bax
bak
bclxl
also
interact
voltagedepend
anionselect
channel
protein
vdac
mediat
cell
death
bim
protein
phosphoglycer
mutas
puma
upregul
modul
apoptosi
wherea
also
interact
bnipl
howev
composit
bclxl
interact
could
differ
differ
cell
type
combin
ip
mass
spectrometri
reveal
bclxl
interact
bad
bax
bak
well
uaca
pawr
flii
tollip
variou
cytoskeleton
protein
viral
ha
hemagglutinin
np
nucleoprotein
protein
rpe
cell
supplementari
tabl
bclxl
interact
pattern
recognit
receptor
ppr
indic
bclxl
potenti
involv
sens
viral
nucleic
acid
bclxl
interact
flii
tollip
indic
could
also
involv
tolllik
receptor
signal
cascad
thu
identifi
novel
interact
partner
bclxl
possibl
bclw
specif
limit
human
noncancer
rpe
cell
disrupt
bclxl
bclw
interact
newli
identifi
partner
may
contribut
iavmedi
death
cell
test
effect
interact
bclxl
newli
identifi
protein
partner
iav
mockinfect
rpe
cell
sdspage
analysi
immunoprecipit
bclxlinteract
protein
demonstr
differ
protein
composit
ip
figur
mass
spectrometri
follow
immonoblot
analysi
protein
candid
show
combin
iav
displac
uaca
bax
bclxl
addit
bad
figur
b
thu
noncytotox
concentr
alter
composit
bclxl
perhap
bclw
interact
iavinfect
cell
figur
iav
activ
trigger
cell
monitor
activ
respons
treatment
iav
infect
rpe
cell
time
observ
combin
treatment
iav
infect
result
enhanc
activ
coincid
declin
rpe
cell
viabil
figur
b
iavinfect
cell
activ
caspas
cleav
substrat
bid
disrupt
basic
cellular
pathway
function
result
inhibit
transcript
translat
cellular
viral
mrna
reduct
product
infecti
iav
virion
supplementari
figur
thu
alter
bclxl
perhap
bclw
interact
activ
trigger
death
iavinfect
cell
interestingli
rpe
cell
transfect
viral
rna
vrna
also
abl
stimul
activ
weakli
figur
caspas
activ
depend
dose
concentr
transfect
vrna
data
shown
howev
insuffici
trigger
death
vrnatransfect
rpe
cell
figur
indic
trigger
cell
death
respons
replic
viru
test
whether
prematur
death
infect
cell
alter
innat
cellular
immun
respons
analys
product
cytokin
iavinfect
rpe
cell
respons
treatment
figur
cytokin
profil
reveal
treatment
attenu
iavmedi
product
rant
interleukin
il
motif
chemokin
interferon
ifn
stimul
product
receptor
antagonist
protein
similar
result
obtain
supplementari
figur
interestingli
vrnatransfect
rpe
cell
ineffect
inhibitor
rant
product
cell
remain
aliv
thu
induc
prematur
death
virusinfect
cell
limit
product
cellular
antivir
proinflammatori
respons
test
effect
standard
mous
model
influenza
mice
challeng
one
lethal
dose
mouseadapt
iav
follow
treatment
mgkg
three
time
interv
first
dose
given
h
infect
surviv
curv
show
iavinfect
anim
die
euthanis
due
excess
weight
loss
wherea
iavinfect
mocktreat
anim
recov
iav
infect
figur
mous
surviv
rate
depend
dose
viral
load
data
shown
investig
effect
treatment
iavinfect
mice
four
mice
differ
treatment
group
kill
day
infect
lung
collect
lung
use
histolog
well
titrat
lung
viral
load
caspas
activ
cytokin
level
abt
treatment
ineffect
viral
replic
figur
activ
figur
lung
inflamm
figur
compar
untreat
iavinfect
mice
howev
observ
signific
imbal
cytokin
product
iavinfect
mice
comparison
untreat
iavinfect
mice
figur
f
imbal
like
result
inabl
immun
system
clear
viru
eventu
lead
death
virusinfect
anim
show
anticanc
structur
analogu
acceler
death
virusinfect
cell
attenu
cellular
antivir
proinflammatori
respons
base
result
propos
mechan
compound
action
virusinfect
noncancer
cell
figur
model
bind
bclxl
bclw
deactiv
cellular
fuse
alter
interact
proapoptot
bad
bax
uaca
virusinfect
cell
bax
bad
dissoci
fuse
mediat
releas
apoptogen
molecul
includ
cytochrom
c
mitochondria
cytochrom
c
form
complex
bclxlfree
uaca
becom
activ
complex
empow
activ
turn
activ
also
activ
virusinduc
faddmedi
apoptosi
pathway
activ
cleav
bid
cleav
bid
acceler
mitochondri
apoptosi
pathway
thu
mutual
amplif
result
dramat
increas
quantiti
repertoir
proteolys
vital
cell
protein
potenti
transit
apoptot
process
execut
return
phase
cell
demis
prematur
cell
death
trigger
inhibit
bclxl
bclw
prevent
develop
cellular
antivir
proinflammatori
respons
initi
cellular
ppr
rigi
retino
acid
induc
genei
respons
viral
surprisingli
found
sever
ppr
compon
pathway
flii
tollip
associ
bclxl
mock
iavinfect
human
rpe
cell
indic
bclxl
bclw
regul
apoptosi
pprsmediat
recognit
viru
compon
vrna
observ
imbal
cytokin
product
iavinfect
mice
associ
inabl
immun
system
clear
viru
eventu
lower
surviv
rate
infect
anim
note
mous
surviv
rate
depend
dose
viral
load
result
nevertheless
warrant
potenti
hazard
effect
therapeut
inhibit
bclxl
bclw
use
deriv
cancer
patient
viral
infect
conclus
anticanc
therapeut
may
acceler
attenu
microbi
infect
cancer
patient
target
host
function
essenti
interplay
howev
anticanc
program
neglect
possibl
evalu
effect
investig
small
molecul
interplay
preclin
trial
typic
perform
pathogenfre
mice
xenotranspl
human
tumour
cell
earli
stage
clinic
trial
focu
tumour
regress
longterm
surviv
without
take
account
potenti
impact
chemotherapeut
agent
conjunct
underli
overt
viral
infect
patient
studi
set
exampl
address
impact
anticanc
molecul
interplay
therapeut
outcom
background
microbi
infect
gemcitabin
obatoclax
purchas
selleck
munich
germani
purchas
activ
biochem
bonn
germani
gossypol
purchas
dtpnci
saliph
provid
jef
de
compound
dissolv
dimethyl
sulfoxid
dmso
sigmaaldrich
st
loui
mo
usa
mm
stock
solut
store
use
human
macrophag
differenti
peripher
blood
mononuclear
cell
isol
healthi
individu
buffi
coat
voluntari
blood
donor
finnish
red
cross
previous
human
telomeras
revers
transcriptaseimmort
retin
pigment
epitheli
htertrp
canin
kidney
mdck
monkey
human
adenocarcinom
alveolar
basal
epithelium
doxycyclineinduc
human
endotheli
slk
cell
line
latent
infect
recombin
kaposi
sarcomaassoci
herp
viru
viru
babi
hamster
kidney
cell
cultur
cell
grown
infect
macrophag
rpe
mdck
cell
influenza
wsn
infb
human
echoviru
sindbi
sinv
semliki
forest
sfv
bunyamwera
bunv
measl
mev
herp
simplex
tick
born
enceph
tbev
dengu
denv
vaccinia
vacv
virus
done
describ
kshv
product
induc
cell
doxycyclin
sodium
titr
infecti
virus
determin
compound
efficaci
test
perform
plate
human
macrophag
rpe
mdck
cell
typic
cell
seed
appropri
cell
growth
medium
grown
h
growth
medium
chang
appropri
viru
studi
compound
ad
medium
dmso
ad
control
well
cell
infect
virus
multipl
infect
moi
noninfect
mock
cell
viabil
measur
use
cell
titr
glo
assay
ctg
promega
southampton
uk
luminesc
read
pherastar
fs
plate
reader
bmg
labtech
ortenberg
germani
use
drug
sensit
score
dss
calcul
efficaci
briefli
curv
fit
base
fourparamet
logist
model
use
graphpad
prism
softwar
http
wwwgraphpadcomscientificsoftwarepr
base
estim
model
paramet
quantit
respons
calcul
express
dss
valu
dss
summaris
area
curv
entir
dose
rang
rel
total
area
threshold
inhibit
favour
ontarget
respons
offtarget
respons
integr
respons
divid
logarithm
bottom
asymptot
logist
model
assess
select
respons
compound
virusinduc
cell
death
differenti
dss
calcul
subtract
mock
control
dss
viru
viral
dss
specif
pathogenfre
femal
balbc
mice
charl
river
laboratori
lentilli
franc
use
anim
hous
temperaturecontrol
environ
lightdark
cycl
receiv
food
water
ad
libitum
group
contain
mice
mice
inocul
intranas
pb
without
two
mouseadapt
strain
hpi
mice
receiv
first
oral
dose
follow
two
dose
interv
dose
mgkg
carrier
ethanol
polyethylen
glycol
phosal
pg
equal
volum
carrier
fed
mock
treatment
group
dose
base
previous
report
toxic
studi
bodi
weight
monitor
daili
mice
lost
initi
bodi
weight
euthanis
cervic
disloc
surviv
data
mous
experi
analys
use
sigmastat
test
statist
signific
test
perform
student
ttest
p
consid
signific
four
mice
per
treatment
group
euthanis
day
postinfect
lung
collect
lung
homogen
prepar
right
lobe
ml
pb
use
microhomogenis
homogen
clear
use
centrifug
g
min
use
viru
titr
determin
cytokin
profil
caspas
activ
assay
describ
left
lobe
lung
fix
neutral
buffer
formalin
embed
paraffin
cut
microtom
thick
slice
stain
hematoxylin
eosin
h
estain
slide
imag
use
panoram
flash
slide
scanner
hungari
imag
process
virtual
whole
slide
upload
web
server
previous
cytokin
profil
perform
use
mous
lung
homogen
supernat
compoundtr
nontreat
iavinfect
noninfect
cell
cytokin
level
measur
use
mous
human
cytokin
array
panel
kit
r
system
minneapoli
mn
usa
membran
expos
xray
film
film
scan
imag
analys
use
imagej
softwar
http
rsbwebnihgovij
addit
level
tumour
necrosi
factor
cell
supernat
assay
elisa
pbl
interferon
sourc
caspas
activ
measur
assay
promega
actin
mrna
level
assay
reversetranscript
strandspecif
qpcr
previous
product
viral
cellular
protein
monitor
use
western
blot
autoradioautographi
briefli
rpe
cell
wash
twice
pb
cover
dmem
without
methionin
sigmaaldrich
contain
bsa
methionin
perkin
elmer
espoo
finland
incub
h
rpe
cell
wash
twice
pb
lyse
sdsload
buffer
sonic
lysat
load
protein
separ
gradient
sdspolyacrylamid
gel
sdspage
biorad
helsinki
finland
protein
monitor
use
radioautographi
visualis
use
typhoon
scanner
ge
healthcar
helsinki
finland
genom
viral
rna
vrna
transfect
experi
viru
grown
mdck
cell
supernat
collect
hpi
viru
pellet
use
ultracentrifug
g
h
viral
rna
purifi
use
rna
extract
kit
qiagen
hilden
germani
rna
transfect
rpe
cell
use
lipofectamin
life
technolog
carlsbad
ca
usa
accord
manufactur
instruct
six
hour
transfect
optimem
media
replac
growth
media
without
h
cell
viabil
caspas
activ
measur
bclxlassoci
factor
immunoprecipit
infect
noninfect
nontreat
rpe
cell
use
rabbit
antibclxl
cell
signal
technolog
danver
usa
antibodi
previous
immunoprecipit
protein
separ
sdspage
visualis
coomassi
stain
entir
lane
sdspage
cut
protein
ingel
digest
trypsin
result
peptid
analys
use
liquid
mass
spectrometri
previous
mass
spectrometri
data
search
use
inhous
mascot
proteinpilot
interfac
swissprot
databas
report
protein
identif
statist
signific
p
immunoblot
protein
separ
use
sdspage
transfer
hybondlfp
pvdf
membran
membran
block
use
milk
trisbuff
salin
tb
incub
primari
guinea
pig
rabbit
antibclxl
cell
signal
technolog
rabbit
antibid
cell
signal
technolog
rabbit
antibax
santa
cruz
biotechnolog
heidelberg
germani
mous
antibad
santa
cruz
biotechnolog
rabbit
antiuaca
sigmaaldrich
rabbit
antinp
mous
thermo
fisher
scientif
dreieich
germani
antibodi
overnight
membran
wash
three
time
min
tb
buffer
contain
tween
tweentb
incub
h
respect
secondari
antibodi
conjug
infrar
dye
licor
bioscienc
koge
denmark
three
wash
min
tweentb
buffer
one
tb
membran
scan
use
odyssey
scanner
licor
bioscienc
immunofluoresc
experi
treat
nontreat
rpe
cell
infect
moi
hpi
cell
fix
paraformaldehyd
pb
pb
bsa
triton
use
block
permeabilis
fix
cell
dilut
antibodi
detect
protein
rabbit
antibclxl
clone
cell
signal
technolog
mous
antibad
clone
santa
cruz
biotechnolog
rabbit
clone
santa
cruz
biotechnolog
antibodi
use
secondari
antibodi
antimous
alexa
fluor
antirabbit
alexa
fluor
conjug
antibodi
life
technolog
nuclei
counterstain
dapi
imag
captur
use
nikon
microscop
process
use
ni
element
ar
softwar
nicon
instrument
melvil
ny
usa
viral
infect
carri
condit
complianc
regul
univers
helsinki
permit
buffi
coat
fraction
voluntari
blood
donor
obtain
permiss
finnish
red
cross
blood
transfus
servic
approv
ethic
review
committe
univers
helsinki
central
hospit
finland
collect
blood
sampl
volunt
approv
ethic
review
committe
univers
helsinki
central
hospit
finland
mous
influenza
viru
infect
experi
carri
condit
authoris
institut
ethic
committe
experiment
anim
vib
depart
molecular
biomed
research
ghent
univers
